Eli Lilly said its experimental antibody treatment, LY-CoV555, being developed with AbCellera for COVID-19, has moved into mid-stage testing and that it is planning final-stage clinical trials in the coming weeks, as reported in This is Money.
Eli Lilly expects efficacy data from the mid-stage trial in the fourth quarter of the year.
"As long as it looks safe, why not push forward?" asked UBS analyst Navin Jacob, adding that "it's all about risk versus reward, and the reward might be huge if something were to work."
Meanwhile, Eli Lilly is also developing another antibody treatment with Chinese drugmaker Shanghai Junshi Biosciences.
To read more NewsPoints articles, click here.